XML 39 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated condensed statements of operations and comprehensive (loss) income - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jul. 03, 2021
Jun. 27, 2020
Jul. 03, 2021
Jun. 27, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net sales $ 109,816 $ 58,017 $ 191,594 $ 136,662      
Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively) 33,503 17,668 55,725 39,077      
Gross profit 76,313 40,349 135,869 97,585      
Selling, general and administrative expense 69,050 40,533 103,736 80,809      
Research and development expense 4,836 2,596 5,783 4,742      
Change in fair value of contingent consideration 641 0 641 0      
Depreciation and amortization 1,852 1,813 3,777 3,638      
Impairment of variable interest entity assets 5,674 0 5,674 0      
Operating (loss) income (5,740) (4,593) 16,258 8,396      
Interest expense (income) 1,681 2,834 (1,195) 5,215      
Other expense (income) 1,645 (1,337) 2,064 (1,254)      
Other expense 3,326 1,497 869 3,961      
Income from continuing operations before income taxes (9,066) (6,090) 15,389 4,435      
(Loss) income before income taxes (9,066) (6,090) 15,389 4,435      
Income tax expense (benefit) 1,714 (110) 1,641 (71)      
Net (loss) income (10,780) (5,980) 13,748 4,506      
Loss attributable to noncontrolling interest 6,654 214 7,062 672      
Net (loss) income attributable to Bioventus Inc. (4,126) (5,766) 20,810 5,178      
Change in foreign currency translation adjustments 23 213 (859) (256)      
Comprehensive (loss) income (10,757) (5,767) 12,889 4,250      
Net income (loss) from continuing operations attributable to common unit holders 6,648 214 6,882 672      
Comprehensive (loss) income attributable to Bioventus Inc. $ (4,109) $ (5,553) $ 19,771 $ 4,922      
Earnings Per Share [Abstract]              
Basic (in dollars per share) [1] $ (0.10)   $ (0.12)        
Diluted (in dollars per share) $ (0.10)   $ (0.12)        
Weighted Average Number Of Shares Outstanding [Abstract]              
Basic weighted average common shares outstanding (in shares) 41,805,347   41,802,840        
Diluted weighted average common shares outstanding (in shares) [1] 41,805,347   41,802,840        
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]              
Weighted average units used in computing basic and diluted net income (loss) per common unit [1] 41,805,347   41,802,840        
Bio Ventus LLC [Member]              
Net sales         $ 321,161 $ 340,141 $ 319,177
Cost of sales (including depreciation and amortization of $5,618, $5,292, $10,854 and $10,599 respectively)         87,642 90,935 84,168
Gross profit         233,519 249,206 235,009
Selling, general and administrative expense         193,078 198,475 191,672
Research and development expense         11,202 11,055 8,095
Change in fair value of contingent consideration             (739)
Restructuring costs         563 575 1,373
Depreciation and amortization         7,439 7,908 8,615
Loss on impairment of intangible assets             489
Operating (loss) income         21,237 31,193 25,504
Interest expense (income)         9,751 21,579 19,171
Other expense (income)         (4,428) (75) 226
Other expense         5,323 21,504 19,397
Income from continuing operations before income taxes         15,914 9,689 6,107
(Loss) income before income taxes         15,914 9,689 6,107
Income tax expense (benefit)         1,192 1,576 1,664
Net income from continuing operations         14,722 8,113 4,443
Loss from discontinued operations, net of tax           1,815 16,650
Net (loss) income         14,722 6,298 (12,207)
Loss attributable to noncontrolling interest         1,689 553  
Net (loss) income attributable to Bioventus Inc.         16,411 6,851 (12,207)
Change in prior service cost and unrecognized (loss) gain for defined benefit plan adjustment         (54) (78) 131
Change in foreign currency translation adjustments         2,126 (322) (334)
Other comprehensive income (loss)         2,072 (400) (203)
Comprehensive (loss) income attributable to Bioventus Inc.         $ 18,483 $ 6,451 $ (12,410)
Weighted Average Number Of Shares Outstanding [Abstract]              
Diluted weighted average common shares outstanding (in shares)         4,900,000 4,900,000 4,900,000
Net income from continuing operations attributable to unit holders         $ 16,411 $ 8,666 $ 4,443
Accumulated and unpaid preferred distributions         (6,133) (5,955) (5,781)
Net income allocated to participating shareholders         (5,895) (1,555)  
Net income (loss) from continuing operations attributable to common unit holders         4,383 1,156 (1,338)
Loss from discontinued operations, net of tax           1,815 16,650
Net income (loss) attributable to common unit holders         $ 4,383 $ (659) $ (17,988)
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share [Abstract]              
Net income (loss) from continuing operations         $ 0.89 $ 0.24 $ (0.27)
Loss from discontinued operations, net of tax           0.37 3.40
Net income (loss) attributable to common unit holders         $ 0.89 $ (0.13) $ (3.67)
Weighted average units used in computing basic and diluted net income (loss) per common unit         4,900,000 4,900,000 4,900,000
[1] Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.’s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.